About compass therapeutics inc - CMPX
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
CMPX At a Glance
Compass Therapeutics, Inc.
80 Guest Street
Boston, Massachusetts 02135
| Phone | 1-617-500-8099 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -66,489,000.00 | |
| Sector | Health Technology | Employees | 39 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CMPX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.866 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.076 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.015 |
CMPX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,704,846.154 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CMPX Liquidity
| Current Ratio | 15.021 |
| Quick Ratio | 15.021 |
| Cash Ratio | 14.956 |
CMPX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -36.678 |
| Return on Equity | -41.294 |
| Return on Total Capital | -32.179 |
| Return on Invested Capital | -39.442 |
CMPX Capital Structure
| Total Debt to Total Equity | 4.995 |
| Total Debt to Total Capital | 4.757 |
| Total Debt to Total Assets | 4.424 |
| Long-Term Debt to Equity | 4.486 |
| Long-Term Debt to Total Capital | 4.273 |